[10Q Detective] Icahn vs. Amlyn Pharma: Round One
1 view
Skip to first unread message
David J. Phillips
Jan 30, 2009, 1:57:07 AM1/30/09
to 10Q_De...@googlegroups.com
Activist investor Carl Icahn is readying for a proxy battle with the management of Amylin Pharmaceuticals (AMLN-$11.03), the drugmaker best known for its diabetic treatment Byetta. The move raises questions about whether Icahn plans to push Amylin for a management shakeup or position the company for a sale. What’s Icahn’s interest in Amylin? Read More….
Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.
Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.
--
Posted By David J. Phillips to 10Q Detective at 1/29/2009 10:50:00 PM
Reply all
Reply to author
Forward
0 new messages